Highest-materiality recent filing
Evofem Q1 net loss $5.5M ($0.04/sh) vs prior net income; sales rise to $0.9M
Net loss $5.5M ($0.04 per share) vs net income $1.0M ($0.01 per share) in Q1 2025.
Evofem signs exclusive 5-year distributorship for SOLOSEC in sub-Saharan Africa with Clovis Davis
Exclusive 5-year distribution agreement with Clovis Davis for SOLOSEC in sub-Saharan Africa, effective April 24, 2026.
Evofem Biosciences extends maturity of Adjuvant convertible notes by six months
Fourth Amendment to Securities Purchase Agreement dated April 10, 2026 with Adjuvant Global Health Technology Fund.
Evofem and Windtree mutually terminate PHEXXI supply agreement, no fees
License and Supply Agreement for PHEXXI manufacturing terminated March 13, 2026, by mutual consent.
Evofem reports FY2025 net sales $20.2M (+4% YoY), income from operations $3.4M vs loss $7.7M
Record net sales of $20.2M in FY2025, fifth consecutive year of growth; up 4% from $19.4M in FY2024.
Evofem posts Q3 2025 operating income of $1.0M; net sales up 10% YoY to $5.0M
Net sales $5.0M in Q3 2025 vs $4.5M Q3 2024; operating income $1.0M vs loss of $2.4M.
Evofem shareholders reject merger with Aditxt; merger terminated
Shareholders voted against merger: 93.2M for, 7.2M against; proposal not approved at Special Meeting on Oct 20, 2025.
Evofem Biosciences Reports Q2 2025 Net Sales of $4.8M, Improves Loss from Operations
Net sales rose 16% to $4.8M in Q2 2025 from $4.2M in Q2 2024, driven by SOLOSEC addition and PHEXXI price increase.
Evofem Biosciences issues $1.42M convertible notes and warrants to Aditxt
Aggregate principal amount $1,423,076.92; warrants to purchase 92,407,592 shares.
Evofem signs exclusive SOLOSEC license for UAE, Kuwait, Saudi Arabia and other Middle East countries
Exclusive 5-year license to develop, market, and sell SOLOSEC in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.
Evofem Q1 net income $1.0M, revenue $0.8M; plans 55-60% PHEXXI COGS cut
Net sales $0.8M, down 78% from $3.6M YoY due to order timing after Q4 2024 stocking.
Evofem issues $1.15M convertible notes to Aditxt as part of merger financing
Issued $1,153,846 principal in senior subordinated convertible notes and warrants to buy 74,925,075 shares to Aditxt.
Windtree to manufacture PHEXXI; Evofem expects COGS reduction of 55-60%.
Evofem reports 2024 net sales up 6% to $19.4M; operating loss improved 57% YoY
2024 net sales $19.4M (+6% YoY); operating loss $7.7M vs $17.8M in 2023, improvement of 57%.
Received OTC notice on Jan 6, 2025: closing bid price below $0.01 for 30 consecutive days violates Minimum Bid Price Requirement.
Evofem extends merger outside date with Aditxt to Jan 31, 2025
Fourth Amendment to Amended and Restated Merger Agreement dated Nov 19, 2024.
Net product sales $4.5M in Q3 2024, down 12% YoY from $5.1M; operating loss improved 31% to $2.4M.
Evofem secures voting agreements for Aditxt merger; Aditxt completes $2.28M preferred investment
Evofem signed voting agreements with Series E-1 stockholders and convertible noteholders to vote in favor of merger with Aditxt subsidiary Adifem.
Evofem gets merger support pacts; secured lenders terminate forbearance, declare default
Institutional investors with rights to ~1.09B common shares (via preferred, convertible notes, warrants) agreed to vote for Aditxt merger.
Evofem raises $2.28M via private placement of Series F-1 Preferred Stock to Aditxt
Aditxt purchased 2,280 Series F-1 Preferred Stock shares for $2,280,000 in a private placement.
Evofem receives $106.8M debt acceleration notice; closes $460K private placement with Aditxt
Future Pak LLC (agent) claims Event of Default under SPA; repurchase price ~$106.8M if all Purchasers exercise Section 5.7 Option.
Evofem receives OTCQB delisting notice for bid price below $0.01
Received OTC Markets notice on Aug 28, 2024 for bid price below $0.01 for 30 consecutive trading days.
Evofem Q2 net sales up 69% to $4.2M; operating loss improves 81% to $1.4M
Net product sales $4.2M (+69% YoY); net income $1.3M ($0.02/share) vs net loss $8.6M ($5.43) in prior year.
Evofem, Aditxt sign amended merger with $1.8M cash and preferred stock
Aditxt to pay up to $1.8M cash for Evofem common stock, less dissenting shares; preferred stock exchange also specified.
Evofem acquires Solosec from Lupin for up to $84M in contingent consideration
Evofem (OTCQB: EVFM) acquired Solosec (secnidazole) from Lupin Inc.; deal closed July 14, 2024.
Evofem Q1 net sales down 38% to $3.6M; loss narrows; Aditxt merger progress
Net sales $3.6M vs $5.8M a year ago, attributed to WAC increase cycle and Change Healthcare cyberattack.
Evofem reinstates merger with Aditxt after termination, secures $1M payment and new terms
On May 2, Evofem, Aditxt and merger sub reinstated the merger agreement after termination on April 26.
Net product sales $18.2M, up from $16.8M in 2022; Q4 sales $4.8M vs $0.2M.
Evofem amends merger with Aditxt; extends proxy deadline, equity investment replaces loan
Third Amendment extends joint proxy statement filing deadline to April 30, 2024.
Evofem reports record Phexxi net sales of $18.1-$18.3M for FY2023, operating expense down >60%
Preliminary 2023 net product sales of $18.1-$18.3M, third consecutive year of Phexxi revenue growth.
Evofem exchanged certain rights and warrants with holders for 22,280 shares of new Series F-1 Convertible Preferred Stock.
Ivy Zhang was appointed as the Chief Financial Officer and Secretary of the Company, effective immediately.
Albert Altro’s appointment as the Company’s interim Chief Financial Officer terminated, effective immediately.
which was left vacant as a result of the resignation by Justin J. File.
On April 5, 2023, the Company’s board of directors appointed Saundra Pelletier to fill the role as the Secretary of the Company, which was left vacant as a result of the resignation by Justin J. File.
In connection with the RIF, the Company terminated the employment of Katherine Atkinson as the Company’s Chief Commercial Officer, effective March 17, 2023.
On March 3, 2023, Justin J. File provided his notice of resignation from his role as Chief Financial Officer of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), to pursue other opportunities.
On March 6, 2023, Albert Altro was appointed as the interim Chief Financial Officer of the Company.
On February 10, 2023, Jenny Yip notified Evofem Biosciences, Inc., a Delaware corporation (the “Company”), of her resignation as member of the Company’s board of directors (the “Board”), effective immediately.
On December 19, 2022 Company appointed Justin J. File as Secretary, effective December 16, 2022.
On October 10, 2022, Alexander A. Fitzpatrick, the General Counsel and Secretary of Evofem Biosciences, Inc. (the “Company”) tendered his resignation to the Company, effective October 14, 2022.
On August 2, 2022, the Board of Directors (the “Board”) of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), elected Jenny Yip, to the Board to fill the existing vacancy on the Board.
On November 17, 2021, William Hall, Ph.D., M.D. notified the Board of Directors (the "Board") of Evofem Biosciences, Inc., a Delaware corporation (the "Company"), of his intention to resign as a member of the Board effective immediately due to health concerns.
Max materiality 0.90 · Median 0.60 · Most common event other_material